Placebo News and Research

RSS

Testosterone, estrogen raise men's risk of heart disease

Why men have more heart disease than premenopausal women has been unclear, but a new study shows that the sex hormones testosterone and estrogen alter cardiovascular risk factors in a way that raises a man's risk of heart disease.

9 Mar 2015

New review finds no link between menopausal hormone therapy and mortality risk

Menopausal hormone therapy (HT) does not have a significant effect on death, according to a new review of the medical literature published over the past three decades.

9 Mar 2015

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.

7 Mar 2015

Oxytocin nasal spray helps healthy men reduce consumption of fatty foods

A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.

6 Mar 2015

Non-viral gene therapy provides relief for diabetics with constant foot pain

Walking barefoot on sand "felt like walking on glass" for Keith Wenckowski, who has lived with type-one diabetes for more than two decades.

6 Mar 2015

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.

5 Mar 2015

Study: Omega-3 fatty acids appear to protect heart function among heart attack survivors

Taking omega-3 fatty acids appeared to lower inflammation and guard against further declines in heart function among recent heart attack survivors already receiving optimal standard care, according to results from a randomized, controlled trial to be presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.

5 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.

4 Mar 2015

Study findings question benefit of giving sedatives before surgery for patients under general anesthesia

Although sedatives are often administered before surgery, a randomized trial finds that among patients undergoing elective surgery under general anesthesia, receiving the sedative lorazepam before surgery, compared with placebo or no premedication, did not improve the self-reported patient experience the day after surgery, but was associated with longer time till removal off a breathing tube (extubation) and a lower rate of early cognitive recovery, according to a study in the March 3 issue of JAMA.

4 Mar 2015

Investigational drug may attack cause of vaso-occlusion crises in sickle cell anemia

Treatment for painful episodes of blood vessel obstruction in sickle cell anemia is currently limited to controlling pain, but an investigational therapy might be able to interfere with the underlying cause of these events, known as vaso-occlusion crises, researchers at Duke Medicine report.

3 Mar 2015

Extending use of bupropion before quitting reduces smoking behavior

Smokers may be more likely to successfully quit their habit if simple adjustments were made to how an existing anti-smoking medication is prescribed, according to a new study by a University at Buffalo research team.

3 Mar 2015

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended JINARC (tolvaptan) for approval.

3 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).

2 Mar 2015

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Transition Therapeutics Inc. announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").

2 Mar 2015

Researchers investigate efficiency of drug research and development

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could be responsible.

28 Feb 2015

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests.

27 Feb 2015

Placebo News and Research

Testosterone, estrogen raise men's risk of heart disease

New review finds no link between menopausal hormone therapy and mortality risk

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Liraglutide may help obese adults achieve weight loss

Oxytocin nasal spray helps healthy men reduce consumption of fatty foods

Non-viral gene therapy provides relief for diabetics with constant foot pain

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Study: Omega-3 fatty acids appear to protect heart function among heart attack survivors

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Study findings question benefit of giving sedatives before surgery for patients under general anesthesia

Investigational drug may attack cause of vaso-occlusion crises in sickle cell anemia

Extending use of bupropion before quitting reduces smoking behavior

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Researchers investigate efficiency of drug research and development

Perceived cost affects placebo response in Parkinson’s disease

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News